Physiotherapist struck off for Botox jabs
Adrian Harding was struck off by the Health and Care Professions Council (HCPC) for administering the injections to treat patients with spasticity between 2008 and 2020 without a prescription or written consent.
He was described as an "extremely experienced" physiotherapist at NPP Neuro Group, which sees patients throughout the West Midlands.
The tribunal found Mr Harding "acted as he pleased" and administered injections despite knowing the drug needed a prescription that he was unable to provide.
A fellow physiotherapist, Dawn Hicklin, supplied Mr Harding with two boxes of injection vials while she was working at City Hospital for Sandwell and West Birmingham NHS Trust in January 2019, the panel heard.
The incident was reported and she was struck off.
Ms Hicklin lied to bosses, the panel said, claiming that the boxes were empty, and that she had not previously provided him with any drug vials.
Following this, in early 2020, Mr Harding told NPP Neuro Group that he would likely be called as a witness as part of an investigation into Ms Hicklin, and that there was "no cause for concern".
By October, he revealed inquiries would be extended to his practice.
Colleagues at NPP Euro Group subsequently audited his records as part of the investigation, and were left in "shock, horror and disbelief" by what they found, the tribunal heard.
The panel said he was "angry" at his employer for raising concerns and "demonstrated a complete lack of insight" of the potential damage he had caused.
Mr Harding was an "acknowledged specialist in his field and lectured on the subject", the HCPC panel was told, and it was likely he "authored the policies that he should have been following and that he had lectured students on such matters".
His record-keeping was described as "so poor it was serious enough to be classed as misconduct".
It was said that many essential records were either missing or incomplete.
Mr Harding was referred to the HCPC on 9 October 2020 by his employer, and self-referred a day later, before retiring by 12 October.
The tribunal found he had not shown any evidence of "reflection, remediation, insight or remorse" and he "simply walked away".
Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram.
Paramedic failed to take paralysed man to hospital
Radiographer struck off for racist language
Health and Care Professions Tribunal Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
2 hours ago
- CNBC
Supreme Court allows Trump's cuts to health research grants over DEI policies
The Supreme Court on Thursday allowed Trump administration broad cuts to National Institutes of Health grants as part of the federal government's campaign against diversity, equity and inclusion policies. But in a mixed decision the court left in place a different part of the lower court judge's ruling that threw out the administration's guidance document that introduced the policy, raising questions about whether it can be applied moving forward. The justices, on a 5-4 vote, granted in part an emergency request filed by the administration seeking to put a Massachusetts-based federal judge's ruling on hold. The court did not fully explain its reasoning, but the majority indicated that groups seeking to challenge the funding cuts have to file separate lawsuits in a different federal venue — the Court of Federal Claims. Conservative Justice Amy Coney Barrett was the deciding vote in crafting the decision. Four justices, all conservatives, said they would have granted the Trump administration's application in full, while four others — conservative Chief Justice John Roberts and the court's three liberals — would have denied it in full. "As today's order states, the District Court likely lacked jurisdiction to hear challenges to the grant terminations, which belong in the Court of Federal Claims," Barrett wrote in a concurring opinion. But, she added, "the Government is not entitled to a stay of the judgments insofar as they vacate the guidance documents." The National Institutes of Health (NIH) is a collection of agencies within the Department of Health and Human Services that receives billions of dollars from Congress to fund medical research at universities, hospitals and other institutions. When President Donald Trump took office in January, he vowed to end so-called diversity, equity and inclusion, or DEI, policies, saying that rather than fostering equality as intended, they are a form of discrimination, primarily against white people. He has also taken aim at policies recognizing transgender rights, including access to gender transition care. The NIH then conducted a review of grants and determined that more than 1,700 of them were not consistent with Trump's directives and terminated them, including studies into HIV prevention and gender identity among teens. The moves were challenged by 16 states led by Massachusetts and the American Public Health Association, among others. After a trial, U.S. District Judge William Young in Massachusetts ruled that the government had failed to follow correct legal processes in implementing the policy, in violation of a law called the Administrative Procedure Act. In rushing to implement Trump's agenda, NIH "simply moved too fast and broke things, including the law," Young wrote. He also said that DEI was "an undefined enemy," noting that government lawyers had not been able to explain exactly what it meant. Young found that there was "pervasive racial discrimination" and "extensive discrimination" against gay, lesbian and transgender people in how grants were selected for termination. He also found "an unmistakable pattern of discrimination against women's health issues." Young declined to put his ruling on hold, as did the Boston-based 1st U.S Circuit Court of Appeals, which also kept the grants intact. In asking the Supreme Court to intervene on behalf of the Trump administration, Solicitor General D. John Sauer argued that the case is similar to another that arose in Massachusetts in which a judge blocked Trump administration plans to terminate teacher training grants on anti-DEI grounds. The Supreme Court in April blocked that ruling on a 5-4 vote. "This application presents a particularly clear case for this court to intervene and stop errant district courts from continuing to disregard this court's rulings," Sauer wrote. Lawyers for the states pushed back on Sauer's narrative, saying it "bears little resemblance to reality, with Young's ruling a "run-of-the mill" example of a court intervening when the government violates the law. The justices Thursday disagreed over whether the April decision governed the outcome in the latest case. In a brief opinion, Roberts, who dissented in the earlier case, said it was different, with Young's findings "well within the scope of the district court's jurisdiction." But conservative Justice Neil Gorsuch, in his own separate opinion, criticized Young for failing to abide by the April decision. "Lower court judges may sometimes disagree with this court's decisions, but they are never free to defy them," he wrote. The Trump administration has regularly turned to the Supreme Court when its broad use of executive power is challenged in court and has prevailed in the majority of cases. Trump and his allies have also harshly criticized judges who have ruled against him.
Yahoo
2 hours ago
- Yahoo
New Jacksonville-area Girl Scout badges to show girls 'who they are,' not how they look
The Jacksonville-based Girl Scouts of Gateway Council has launched a Body Appreciation Program, complete with badges, to help girls value their abilities over their appearance. The Gateway Council, which serves about 6,500 girls in 35 North Florida counties, cited survey data from the Girl Scouts of the USA. 'Research makes it clear that body image pressures starts as early as 7 years old, and those pressures and influences can shape how girls see themselves for years to come," Gateway CEO Wendy Dordel said. "Girls deserve to grow up knowing their worth isn't tied to how they look, but to who they are and what they can do." Each of the new badges available to the different age levels of Girl Scouts have distinct goals. Among the badges are "Beyond the Mirror," which teaches cadette level scouts to "see through the hype" of beauty standards in the media and be authentic. A senior level badge called "Mind, Body, Me" shows them how to use the mind-body connection to boost overall wellness. Flamingo, a women's body care company, donated $1 million to support the program. "We believe self-care goes beyond products — it's about showing up for yourself with confidence and compassion," Vice President Vikki Williams Cornwall said. Wakefield Research surveyed 1,000 U.S. girls ages 5 to 13 over a two-week period in June. Here is more of the data: About 96% of the girls said they like their appearance, but 37% wish they could change something about it — a number that increases to 50% for girls ages 11 to 13. The girls were asked if they get more compliments on their appearance or their abilities. Half of girls ages 5 to 7 said they receive more praise about how they look, but that reversed in older girls. About 66% of the girls ages 8 to 10 and 64% of ages 11 to 13 reported that people focused more on their abilities than their appearance. "These mixed messages can erode girls' self-worth, making it essential to shift the focus toward valuing bodies for their abilities, not their appearance," according to the Gateway council. The girls were asked how they wanted to be described: About 36% of them in all age groups surveyed said smart, while 17% said funny and another 17% said creative. Girls as young as 5 years old said they heard the women in their lives talk negatively about the way they look. That increased with older age groups: 52% of girls ages 8 to 10 reported that they heard negative comments "a lot or sometimes" and 41% of ages 11 to 13 said they hear them "all the time or sometimes." The Body Appreciation program and its badge curriculum program was developed with expert mental health and youth development advisors. Also, "insight" from a national pilot program with troop leaders and scouts was used, according to Gateway. bcravey@ (904) 359-4109 This article originally appeared on Florida Times-Union: Girl Scout body-image badges combat society's mixed messages Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
Advancing rare disease trials by overcoming patient recruitment challenges
Next month, clinical development and clinical operations professionals will gather and discuss the current challenges in running clinical trials for orphan drugs and rare diseases at the 3rd Annual Clinical Trials in Rare Diseases (CTRD) meeting in Princeton, New Jersey. The meeting, which will take place 17–18 September, will bring together experts from the pharmaceutical and biotech sectors to discuss, not only the obstacles and solutions to clinical trial operational issues, but also to explore the evolving landscape of clinical trials for rare diseases, with a strong emphasis on innovation, collaboration, and patient-centric approaches. At the same venue, the 3rd Annual Clinical Data Management Innovation (CDMI) will explore ways to streamline data entry and collection at trial sites, make better use of real-world evidence, and address the evolving regulatory environment around clinical data. Both meetings will run in parallel at the same venue in Princeton, New Jersey. The Clinical Trials in Rare Diseases meeting will kick off with a case study on how artificial intelligence (AI) is accelerating rare disease drug development. During the talk, Bruce Bloom, CEO of Fortuity Pharma, will map out processes for pre-IND packages, working with the US Food and Drug Administration (FDA), and explore both the challenges and successes of applying AI in such trials. At the CDMI conference, a keynote by Jeff Malavasi, Associate Director of Information Security and Data Compliance of the Cambridge, Massachusetts-based biotech Scholar Rock, will focus on the growing cybersecurity challenges created by the digital transformation of clinical trials. His talk will also provide a practical framework for adopting AI-driven security solutions, including zero-trust architectures and automated response protocols, to safeguard sensitive clinical data. Building on the theme of AI, Aamir Jaka, Global Vice President of the clinical analytics company Saama, will laterexplore how agentic AI is moving data management beyond traditional rule-based automation. Patient recruitment is a persistent challenge in rare disease research On the same day, Jamie Switzer, Associate Director of Clinical Operations at Insmed, will present a case study on strategies to keep trials on schedule while tackling the issue of patient recruitment. Earlier this month, Insmed's drug Brinsupri (brensocatib) was approved to treat non-cystic fibrosis bronchiectasis by the FDA based on results from the Phase III ASPEN (NCT04594369) and Phase II WILLOW (NCT03218917) studies. Switzer will provide practical solutions to patient recruitment problems, while a subsequent panel discussion featuring industry leads from Alexion, Insmed, Asklepion Pharmaceuticals, and BioMarin will take the conversation further to discuss innovative ways to engage patients. Patient recruitment and patient advocacy will be a recurring theme throughout the conference, with speakers sharing insights and emphasising the importance of having patient advocacy organisations as an indispensable partner to extend trial reach, co-design protocols, and foster genuine patient-centered practices. Patient centricity will also be a key theme in the CDMI meeting, where Dinesh Pillaipakkamnatt, former Director of Merck & Co, will highlight how to create a more personalised trial experience, while also considering data privacy, adoption barriers, and the safe handling of large volumes of sensitive information. Tackling operational challenges with clinical trials The second day of both meetings will commence with interactive roundtable discussions on topics such as importance of decentralising rare disease trials, strategies to overcome patient retention barriers, best practices for managing external data and addressing issues of identity, integration, and privacy while enabling patient-centric data management, across both the conferences. The patient and caregiver perspective with rare disease research will be explored with Leigh Dallow, Patient Advocate & Caregiver, sharing her experience around trial participation, discussing trial enrollment decisions, and patient burden, in the CTRD meeting. In a subsequent session, an expert from the Rare Disease Diversity Coalition will discuss the issues of inclusion and diversity in rare disease trials, focusing on underrepresented populations and ways to ensure fair access to therapies and research opportunities. In the afternoon, the focus will shift to the strategic and operational elements of rare disease drug development. In a fireside chat, Bloom and Paul Lupo of PTC Therapeutics will discuss issues such as how to select a CRO and how to work with small patient populations. Another fireside chat, led by Kinjal Patel and Janine Sampong, both with Mitsubishi Tanabe Pharma America, will examine how to accelerate timelines when working with clinical sites and propose strategies to attract attention of academic organisations, and build strong partnerships. Concurrently, the second day of the CDMI meeting will feature several sessions on successful strategies for CDM vendor selection and outsourcing models, an important update on ICH E6(R3) guidelines and its implications for clinical data management, and the implications of AI and machine learning for clinical data management. The meeting will conclude with a case study on CRO and sponsor collaboration, emphasising the importance of improving partnerships and aligning financial incentives. The 3rd Annual Clinical Trials in Rare Diseases and the 3rd Annual Clinical Data Management Innovation conferences are hosted by Arena International Events Group, a B2B events company owned by GlobalData, the parent company of Clinical Trials Arena and Pharmaceutical Technology. Click here to read the agenda for the conference for 3rd Annual Clinical Trials in Rare Diseases and the 3rd Annual Clinical Data Management Innovation. "Advancing rare disease trials by overcoming patient recruitment challenges" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
